1. ALLA AKTIER
  2. NYHETER
  3. CANTARGIA

Cantargia

Nyheter Cantargia Nyheter alla bolag
Affiliate
Courtagefri handel på Nordnet till sista juni 2027! Har du inget konto på Nordnet så är det verkligen läge att skaffa ett. Just nu får nya kunder courtagefri handel till sista juni 2027. Läs mer om erbjudandet och skapa ditt konto här
Erbjudandet gäller nya kunder och omfattar handel via Nordnets app eller hemsida i nordiska aktier, ETF:er, teckningsrätter och teckningsoptioner. För fullständiga villkor se nordnet.se/jubileum. Kom ihåg att investeringar alltid innebär en risk.

Invitation to presentation of Cantargia’s report for the first half of 2023 on August 22 at 3.00 p.m. CEST

Cantargia AB will publish the company’s interim report for the first half of 2023 on Tuesday, August 22, 2023, at 08:30 a.m. CEST.

In conjunction to the report, Cantargia invites investors, analysts, and media to an audiocast with teleconference (in English) on August 22, at 3:00 p.m. CEST, where Göran Forsberg, CEO, and Cantargia’s new CFO, Patrik Renblad, will present Cantargia and comment on the interim report, followed by a Q&A-session.

If you wish to participate via webcast, please use the link below. Via the webcast you are able to ask written questions. Webcast: https://ir.financialhearings.com/cantargia-q2-2023

If you wish to participate via teleconference, please register on the link below. After registration you will be provided phone numbers and a conference ID to access the conference. You can ask questions verbally via the teleconference.

https://conference.financialhearings.com/teleconference/?id=200932

The webcast will also be available on demand on Cantargia’s corporate website: www.cantargia.com

Contact
Göran Forsberg, CEO
Telephone: +46 (0)46-275 62 60
E-mail: goran.forsberg@cantargia.com

About Cantargia
Cantargia AB (publ), reg. no. 556791-6019, is a biotechnology company that develops antibody-based treatments for life-threatening diseases and has established a platform based on the protein IL1RAP, involved in a number of cancer forms and inflammatory diseases. The main program, the antibody nadunolimab (CAN04), is being studied clinically primarily in combination with chemotherapy with a focus on pancreatic cancer, non-small cell lung cancer and triple-negative breast cancer. Positive interim data for the combinations indicate stronger efficacy than would be expected from chemotherapy alone. Cantargia’s second development program, the antibody CAN10, blocks signaling via IL1RAP in a different manner than nadunolimab and addresses treatment of serious autoimmune/inflammatory diseases, with initial focus on systemic sclerosis and myocarditis.
 
Cantargia is listed on Nasdaq Stockholm (ticker: CANTA). More information about Cantargia is available at www.cantargia.com.

Attachments
Invitation to presentation of Cantargia’s report for the first half of 2023 on August 22 at 3.00 p.m. CEST

Datum 2023-08-14, kl 10:00
Källa MFN
Bifogade filer
Invitation to presentation of Cantargia’s report for the first half of 2023 on August 22 at 3.00 p.m. CEST